Is BNGO an ARKK?

Is BNGO an ARKK?

Ark Invest’s Chapter in the BNGO Stock Story

The fund manager has sent some public praise BNGO’s way. Ark even has a special portfolio — Ark Genomic Revolution ETF (NYSEARCA:ARKG) — for just that sort of stock material.

Similarly, Is BNGO a good buy?

Based on his analysis, DeGeeter rates BNGO stock as « outperform » with a $14 value. Other analysts are also bullish on the company. Those tracked by the Wall Street Journal have BNGO rated as a consensus « buy » with an average $12 price target.

Does Ark buy BNGO? Investors who want to start a position in BNGO may want to act before Ark does, because once Ark announces it has bought, expect shares of Bionano to shoot through the roof.

Rate this article.

Perf. YTD -36.05%
52W low -8.02%
PE Ratio 0
MKT Cap 506.82M

• Feb 22, 2021

Thereof, Is BNGO a meme stock?

Admittedly, it has been a while since Bionano Genomics (NASDAQ:BNGO) stock has been a « hot stock, » a « meme stock » or whatever you want to call it. Since its big drop in late February and early March, the market has had mixed feelings about this life sciences company.

Is BNGO a pump and dump?

BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.

Who owns Bionano genomics?

Top 10 Owners of Bionano Genomics Inc

Stockholder Stake Shares owned
BlackRock Fund Advisors 5.74% 16,609,007
The Vanguard Group, Inc. 4.86% 14,064,639
SSgA Funds Management, Inc. 2.49% 7,198,880
Geode Capital Management LLC 1.63% 4,714,883

Is BNGO expected to rise?

Bionano Genomics Inc (NASDAQ:BNGO)

The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +262.32% increase from the last price of 2.07.

Will BNGO get FDA approval?

The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.

What does Bionano genomics do?

Bionano Genomics, Inc. provides a platform to analyze the long segments of genomic DNA and other biomolecules structural variations. The Company offers proprietary nanochannel chips, automated imaging instrument, integrated primary and secondary software, and application specific reagents.

What institutions are buying NIO?

Largest shareholders include Baillie Gifford & Co, BlackRock Inc., Vanguard Group Inc, State Street Corp, VWIGX – Vanguard International Growth Fund Investor Shares, Susquehanna International Group, Llp, Goldman Sachs Group Inc, Citadel Advisors Llc, VEIEX – Vanguard Emerging Markets Stock Index Fund Investor Shares, …

Is BNGO an American company?

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. … The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

What institutions are buying BNGO?

Bionano Genomics (NASDAQ:BNGO) Institutional Buying and Selling

Reporting Date Hedge Fund Ownership in Company
2/14/2022 Nuveen Asset Management LLC 0.357%
2/14/2022 Barclays PLC 0.123%
2/14/2022 GSA Capital Partners LLP 0.019%
2/14/2022 Mutual Advisors LLC 0.017%

How much will BNGO be worth?

Future price of the stock is predicted at 4.5918222008586$ (120.231% ) after a year according to our prediction system. This means that if you invested $100 now, your current investment may be worth 220.231$ on 2023 April 13, Thursday.

What is Nio price target?

The 29 analysts offering 12-month price forecasts for NIO Inc have a median target of 32.94, with a high estimate of 86.57 and a low estimate of 24.08. The median estimate represents a +67.62% increase from the last price of 19.65.

What type of stock is BNGO?

Common Stock (BNGO)

Does Cathie own BNGO?

Is Cathie Wood Invested in BNGO? As of the time of this writing, it does not appear that Cathie Wood or ARK are invested in Bionano Genomics. The firm’s genomics and biomedical ETF, ARKG, currently contains 52 individual holdings.

What is a Bionano chip?

Built using proprietary Nanochannel technology, Bionano Chips for the Saphyr® and Irys® systems linearize DNA, enabling high-speed, high-throughput optical genome mapping and structural variation detection for a variety of applications including human and clinical research.

Is it too late to buy AMC shares?

So, is it too late to purchase AMC stock? The price after a short squeeze eventually fall back down and level out, but this will take time. With AMC stock trading below $100, now could be the perfect time to buy.

What kind of company is Bionano Genomics Inc?

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space.

Where is BNGO located?

The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Who are Bionano genomics competitors?

13 Competitors

BioNano Genomics’s competitors are BioDiscovery, Fluxion Biosciences, IRX Therapeutics, Hepregen, Genvault Corporation and more.

Who owns the most stock in NIO?

Top 10 Owners of NIO Inc

Stockholder Stake Shares owned
BlackRock Fund Advisors 2.99% 40,093,147
The Vanguard Group, Inc. 2.76% 36,994,474
SSgA Funds Management, Inc. 2.45% 32,887,731
Goldman Sachs & Co. LLC (Private … 1.73% 23,202,778

What percent of NIO is public?

Public Company Ownership

Public companies currently own 8.5% of NIO stock. It’s hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it’s worth watching this space for changes in ownership.

What hedge funds are buying NIO?

NIO (NYSE:NIO) Institutional Buying and Selling

Reporting Date Hedge Fund Ownership in Company
3/9/2022 Norges Bank 0.864%
2/25/2022 Garde Capital Inc. 0.000%
2/23/2022 Resources Investment Advisors LLC. 0.001%
2/23/2022 BlackRock Inc. 4.081%

Join TheMoney.co community and don’t forget to share this post !

Quitter la version mobile